Transmembrane signaling plays a central role in virtually every aspect of human physiology. Andrew Kruse's research aims to elucidate the molecular basis of membrane protein signaling through the use of biophysical techniques and structural biology, as well as cell-biological approaches. Specifically, he is focused on the study of cell surface receptors that play important roles in human physiology and disease, such as the angiotensin II type 1 receptor and the RXFP1 relaxin receptor.  His group also employs combinatorial protein engineering approaches to identify synthetic antibody fragments to modulate receptor signaling and to serve as potential therapeutic agents.

Andrew C Kruse, a 2016 Vallee Scholar, is Professor of Biological Chemistry and Molecular Pharmacology at Harvard Medical School. Prior to joining the faculty at Harvard, he completed doctoral training with Brian Kobilka at Stanford University where he studied neurotransmitter receptor structure, function, and pharmacology. He was selected for the 2016 Forbes “30 under 30” list, and is the recipient of a Smith Family Award for Excellence in Biomedical Research, a Klingenstein-Simons Fellowship, an NIH Director’s Early Independence Award, and the ASPET John J Abel Award.

Kruse Lab